Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients

2008 ◽  
Vol 2008 ◽  
pp. 258-259
Author(s):  
M.T. Hawn
2007 ◽  
Vol 65 (2) ◽  
pp. 185-195 ◽  
Author(s):  
Virender K. Sharma ◽  
Kenneth K. Wang ◽  
Bergein F. Overholt ◽  
Charles J. Lightdale ◽  
M. Brian Fennerty ◽  
...  

2012 ◽  
Vol 142 (5) ◽  
pp. S-110 ◽  
Author(s):  
Yuankai Tao ◽  
Osman O. Ahsen ◽  
Tsung-Han Tsai ◽  
Chao Zhou ◽  
Hsiang-Chieh Lee ◽  
...  

2010 ◽  
Vol 71 (5) ◽  
pp. AB117-AB118 ◽  
Author(s):  
David E. Fleischer ◽  
Bergein F. Overholt ◽  
Virender K. Sharma ◽  
Alvaro Reymunde ◽  
Michael B. Kimmey ◽  
...  

2012 ◽  
Vol 75 (4) ◽  
pp. AB459-AB460 ◽  
Author(s):  
Jan Martinek ◽  
Magdalena Stefanova ◽  
Stepan Suchanek ◽  
Filip Zavada ◽  
Alice Strosova ◽  
...  

2011 ◽  
Vol 73 (4) ◽  
pp. 682-690 ◽  
Author(s):  
Lorenza Alvarez Herrero ◽  
Frederike G.I. van Vilsteren ◽  
Roos E. Pouw ◽  
Fiebo J.W. ten Kate ◽  
Mike Visser ◽  
...  

Endoscopy ◽  
2018 ◽  
Vol 50 (10) ◽  
pp. 953-960 ◽  
Author(s):  
Gargi Pandey ◽  
Mubashir Mulla ◽  
Wyn Lewis ◽  
Antonio Foliaki ◽  
David Chan

Abstract Background Barrett’s esophagus (BE) is a premalignant condition characterized by replacement of the esophageal lining with metastatic columnar epithelium, and its management when complicated by low grade dysplasia (LGD) is controversial. This systematic review and meta-analysis aimed to determine the efficacy of radiofrequency ablation (RFA) in patients with LGD. Methods MEDLINE, EMBASE, and Web of Science were searched for studies including patients with BE-associated LGD receiving RFA (January 1990 to May 2017). The outcome measures were complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D), rates of progression to high grade dysplasia (HGD) or cancer, and recurrence. Results Eight studies including 619 patients with LGD (RFA = 404, surveillance = 215) were analyzed. After a median follow-up of 26 months (range 12 – 44 months), the overall pooled rates of CE-IM and CE-D after RFA were 88.17 % (95 % confidence interval [CI] 88.13 % – 88.20 %; P < 0.001) and 96.69 % (95 %CI 96.67 % – 96.71 %; P < 0.001), respectively. When compared with surveillance, RFA resulted in significantly lower rates of progression to HGD or cancer (odds ratio [OR] 0.07, 95 %CI 0.02 – 0.22). The pooled recurrence rates of IM and dysplasia were 5.6 % (95 %CI 5.57 – 5.63; P < 0.001) and 9.66 % (95 %CI 9.61 – 9.71; P < 0.001), respectively. Conclusions RFA safely eradicates IM and dysplasia and reduces the rates of progression from LGD to HGD or cancer in the short term.


Sign in / Sign up

Export Citation Format

Share Document